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Abstract: The evolution of supportive care in lung cancer (LC) is 
the focus of this article, which aims to present an overall picture 
of the developments in the field, highlight milestones over the past 
four decades, and provide directions for future research and prac-
tice. Although in the 1970s this study was minimal, from the 1980s 
onwards, there was an expansion of the range of topics covered in 
the literature, reflecting the importance of supportive care to clini-
cal practice. These areas include the identification of supportive care 
needs in LC, symptoms and symptom management, psychosocial 
aspects and coping with LC (including support of caregivers), qual-
ity of life issues and the development and testing of patient-reported 
outcomes, the option of best supportive care versus treatment, smok-
ing cessation before and after diagnosis of LC, and service delivery 
models. This article celebrates the evolution of supportive LC care 
over the past 40 years alongside recognizing that more work needs 
to be done in the future and new research foci need to be developed 
to meet the current needs of patients with LC. The role and the con-
tinuous efforts of the International Association of the Study of Lung 
Cancer, including the sixteenth World Conference on Lung Cancer 
in 2015 to meet this goal, will be crucial and strategic in the future.
Key Words: Lung cancer, Symptoms, Quality of life, Psychosocial, 
Tobacco control, Models of care, Review.
(J Thorac Oncol. 2015;10: 10–18)
Supportive care in lung cancer (LC) and its evidence-base 40 years ago was almost nonexistent, with not even a single 
related research article published specifically focusing on LC. 
Caring for patients with LC in the 1970s brings back memo-
ries of patients dying quickly, in distress, gasping for breath 
and in pain. However, the past 40 years have shown a marked 
improvement in the supportive and palliative care for patients 
with LC. To date, supportive care has contributed in signifi-
cant improvements to quality of life in LC. Supportive care in 
the context of this article is defined as a focus on promoting 
and sustaining wellbeing, enhancing capacity to cope with the 
demands of diagnosis and treatment to ensure optimal patient 
experience and outcome irrespective of prognosis—that is, 
as opposed to physiological support (e.g., biologic response 
modifier use, etc.). The rapid growth in the evidence around 
supportive care since the mid 1980s has identified the patients’ 
needs, personal and psychosocial characteristics contributing 
to better prognosis, the role of supportive care in the survival 
of patients, and quality of life issues. The identification of 
the range of symptoms affecting patients and the develop-
ment and testing of symptom management interventions has 
escalated. Recently, the literature has focused on survivorship 
issues, an oxymoron in the care of patients with LC as recently 
as 15 or so years ago. Tobacco control efforts have also had 
a direct (i.e., improved breathing) or indirect impact (i.e., 
through treatments being more effective or leading to fewer 
side effects) on the supportive care of patients with LC. The 
40th anniversary of the International Association of the Study 
of Lung Cancer (IASLC) warrants a review of the progress of 
supportive care for patients with LC. This article aims to high-
light these milestones and broad clinical messages based on 
the history of publications, and provide directions for future 
research and practice.
OVERVIEW OF EARLY STUDIES OF  
SUPPORTIVE CARE EFFORTS
During the 1970s into the early 1980s supportive care of 
patients with LC was largely provided by allied health profes-
sionals and publications in this area focused on case-driven 
issues of palliative and end-of-life care. Little original clinical 
research was reported and there was a gap in the continuum of 
therapeutic care to end-of-life. Changes in smoking patterns 
in parts of the world began to result in a change in the disease 
of LC and in the options available to those with the disease. 
The multidisciplinary approach to research and education in 
LC, in large part driven by the IASLC, was yet to make an 
impact on supportive care options during the 1970s.
A growing body of evidence for supportive care became 
more obvious in the 1980s. Clinical studies on quality of life 
and, later, patient-reported outcomes (PROs) led to the devel-
opment and call for validity testing of LC-specific Quality of 
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life instruments in the 1980s and 1990s. Another practice-
changing theme in the 1980s centered around the explora-
tion of performance status (initially recognized as early as 
the 1950s), age, psychosocial support, and emotional health’s 
effects on the overall prognosis of patients treated with radia-
tion and chemotherapy for LC.1,2 Conclusive evidence was 
found for the positive effect of good performance status on 
overall prognosis, a treatment tenant that still holds true to 
date.1,2 Studies in the 1980s also examined the relationship 
of continued smoking and prognosis with conflicting results3,4
Finally, research in the 1980s began to focus on long-
term survivors and the complications of successful treatment. 
Specifically, this research suggested that prophylactic brain 
irradiation in small cell LC was related to long-term cogni-
tive changes and also described secondary leukemias in survi-
vors who had received multiagent chemotherapy for small cell 
LC.5,6 Finally, the overall theme of supportive care in the 1980s 
and 1990s critically evaluated the risk and benefits of treat-
ment in alleviating symptom distress and maintaining quality 
of life. Each of these trends in the literature will be examined 
more closely for their contribution to care of patients with LC.
STUDY OF SYMPTOM MANAGEMENT
At the time of diagnosis 84% of the patients suffer from 
locally advanced or metastatic disease7 of poor prognosis; sta-
bilization of the disease and symptom management are there-
fore the main focus of supportive care. People with LC have 
a complex array of supportive care needs that have an impact 
on various life aspects; however, our knowledge still remains 
fragmentary.8 A wide spectrum of health care needs was evi-
dent in the systematic review by Maguire et al.8 According to 
the latter review,8 needs were classified into eight domains: 
physical, daily living, emotional, spiritual, informational, 
communication, social, and cognitive. Regarding the physi-
cal domain, common symptoms reported by newly diagnosed 
patients with LC included fatigue, pain, dyspnea, cough, and 
insomnia.9 The need for information on coping with distress 
and physical impairment was also identified.8
Symptom control remains one of the key areas of unmet 
needs among patients with LC. In the 1980s, in the area of 
symptom management, the majority of the research focused 
on using total parenteral nutrition to reverse cachexia associ-
ated with LC, concluding that the risks associated with total 
parenteral nutrition were much greater than the benefits in 
prognosis and that successful treatment of cancer was the 
most effective treatment of cancer cachexia.10,11 Other study 
focused on the patient’s perception of dyspnea, causes and 
treatment for dyspnea, guidelines for treatment of chemo-
therapy-related side effects (specifically nausea and vomiting 
and renal insufficiency with cisplatin), pain control and home 
care guidelines for patients with LC, as care moved from pri-
marily hospitals to outpatient settings.11,12 In the 1990s, more 
study focused on the management of dyspnea, pain, fatigue, 
anorexia/cachexia, and psychological distress. Dyspnea is 
the most common symptom in LC that has been subjected to 
research, from descriptive to pharmacological13 and nonphar-
macological intervention studies and reviews.14,15 It is worth 
noting that many of the interventions tested were not found 
effective,13,16 with studies often experiencing recruitment and 
attrition problems among other methodological limitations.
It is interesting to note that the symptom focus in LC is 
fairly unbalanced, and whereas some symptoms (i.e., dyspnea, 
nausea/vomiting) are a strong focus of research, other common 
symptoms (i.e., cough, fatigue, peripheral neuropathies) have 
attracted minimal or no study. Cough, a symptom experienced by 
a large percentage of patients is worth mentioning as an example, 
as a recent systematic review has shown that there is evidence 
of no effect in some of the interventions we currently use or 
evidence is based on research carried out in the 1960s–1980s, 
with no LC interventional work on cough available in more 
recent years and with no high quality trials available.17 Symptom 
research in the future needs to focus on a wider range of symp-
toms, and co-occurring symptoms (e.g., depression and fatigue) 
to build a stronger evidence base for their management.
Sequentially, research over the past decade has moved 
to characterize symptom clusters in LC18. Awareness of other 
co-existing symptoms is relevant because it influences clini-
cal decision-making as does determining if a symptom is dis-
ease- or treatment-related. Several symptom clusters (i.e., two 
or more concurrent symptoms influencing each other) have 
been described in the LC symptom research and are evident 
in patients with advanced disease, including the gastrointes-
tinal distress cluster, defined as containing nausea, fatigue, 
anorexia, weight loss, altered taste and vomiting,19 and the 
respiratory distress symptom cluster, defined as containing 
breathlessness, cough, and fatigue.20 This conceptualization 
provides a new thinking around how to develop complex inter-
ventions in LC care, as interventions focusing on single symp-
toms have largely being disappointing to date.
Noteworthy is the contribution of (early) supportive and 
palliative care in LC on survival and treatment compliance.21–23 
The leading article by Temel et al.23 mainly demonstrated that 
supportive care might influence survival, whether this effect is 
direct or indirect (improvement in decision-making quality about 
using or not using third-line treatment, education regarding the 
illness, coping and planning ahead) is unclear. In a follow-up 
article, it was also emphasized that there were three particular 
areas in the outpatient visits that early supportive care was deliv-
ered at: symptom management, patient and family coping, and 
understanding of illness.24 On the other hand, Weeks et al.25 sug-
gested that patients’ expectation about chemotherapy are overes-
timated (i.e., up to 40% of the patients believed that the chance 
for chemotherapy to cure cancer is likely or very likely) and that 
patient’s expectation about chemotherapy as a curative treatment 
of metastatic LC is higher when empathy of the patient–doctor 
relationship is high. This is probably a clue that physicians are 
sometimes more confident in chemotherapy (and therefore too 
optimistic about their effects), than they are confident in the 
value of supportive care. Hence, a change in paradigm in the 
care of metastatic LC may need to take place by considering che-
motherapy as a part of the palliation together with other support-
ive methods, insofar as the primary end point, from the patient’s 
point of view, is symptom alleviation and global improvement 
(or at least stabilization) of quality of life.
New clinical issues in symptom control that first 
appeared in the latter 2000s include the side effects of tyrosine 
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kinase inhibitors, which were introduced as possible treatment 
options for LC. This resulted in new toxicities such as acne-
iform rash, hypomagnesaemia, diarrhea, and hypertrichosis 
for which management protocols have been published.26 The 
discovery of new driver mutations in non–small-cell LC has 
moved on apace in the past years leaving us with more oppor-
tunities for targeted treatment.27 This comes, however, at the 
cost of toxicity we do not fully understand yet. Efforts should 
be made to assess toxicity based on robust datasets.
Furthermore, the development of newer antiemetics 
combined with older agents is a topic of ongoing research. 
Finally, the detection of single nucleoid polymorphisms in 
human genes might provide health providers in the future with 
information on identifying early patients at risk for toxicity.28,29
Overall, unmet supportive care needs in patients with 
LC can be visualized by the assessment of quality of life in 
daily clinical practice and that ongoing research in symptom 
management and treatment-induced toxicity is warranted. 
Supportive care needs in LC are changing due to changes in 
health care delivery and LC treatment. Hence, the needs of 
patients with LC should be evaluated on an ongoing basis.
PSYCHOSOCIAL ASPECTS OF COPING WITH LC
The 1980s researchers addressed issues of symptom man-
agement and social isolation that LC patients experienced related 
to dyspnea, fatigue, and weakness.30,31 Research also revealed 
the relationship of social support and survival.2,30,31 Furthermore, 
patients exposed with asbestos in the 1950s were developing 
mesotheliomas in increasing numbers during the 1980s, having 
the added psychological stress of filing personal injury lawsuits 
against asbestos manufactures and former employers.32 The con-
cept of LC stigma was examined, as many LC patients felt the 
perceived discrimination of their caregivers and medical care 
team making them feel responsible for causing their cancer.33,34 In 
the United Kingdom, patients expressed fears that their national 
health insurance would stop treatment for patient-caused diseases 
associated with obesity and smoking.
A key psychosocial aspect in LC is the shame brought 
by the self-inflicted social representation of LC. In an article 
by LoConte et al.,35 a group of patients with non–small-cell 
LC was compared with a group of patients with either breast 
cancer or prostate cancer. The authors have shown that patients 
had higher levels of perceived stigma related to cancer when 
compared with patients suffering from prostate cancer or 
breast cancer. Their smoking status might have significantly 
correlated with high levels of guilt and shame.36 The stigma 
many patients felt spilled over to a lack of funding for research 
in LC.33 The Roy Castle Foundation and Macmillan Cancer 
Relief in the United Kingdom and the Bonnie Addario Lung 
Cancer Foundation in the USA are all successful funding 
efforts for LC research that came from a personal experience 
of LC. With an increase in incidence in LC in never smokers 
this stigma has taken on a new significance. The conclusions of 
one group of researchers about stigma, shame, and blame was: 
“The stigma attached to LC, both “felt” and “enacted,” can 
have a serious effect on people’s lives.” (p.4).33 Furthermore, 
stigma seems to be associated with psychosocial and physical 
health outcomes,37 primarily anxiety and depression37,38; these 
data clearly point to the need of developing interventions to 
help patients manage LC-related stigma.
Social interaction with friends and families may suffer, 
and fear of disclosure may affect people financially or prevent 
them from seeking support.”33 Depression and its association 
with LC diagnosis, treatment and the course of disease have 
been reviewed multiple times over the past three decades.39–42 
Depression in LC has been evaluated worldwide and was 
shown to be associated with poor performance status and poor 
outcomes although it remains under-diagnosed and under-
treated even to date. In a review of studies between 1966 and 
2003, it was shown that one in four of patients with LC expe-
rienced periods of depression during their illness, with those 
not offered treatment and those with small cell LC being at 
higher risk than other LC diagnoses.43 Some reports show the 
incidence of depression to be even higher to approximately 
50% in newly diagnosed patients with LC44 or around one in 
three in metastatic LC.45 Nevertheless, irrespective of the var-
ied incidence of depression reported in past studies, it is clear 
that depression is a common problem in LC, which should be 
identified early and managed appropriately in clinical practice.
In 2005, Brown et al.42 examined the correlations among 
fatigue, systemic inflammatory response, and psychologi-
cal distress and found that fatigue and poor physical function 
was more related to Karnofsky Performance status and psy-
chological distress than weight loss and anemia. The inclu-
sion of psychosocial support, support groups, counseling and 
pharmacological interventions for patients experiencing LC 
from diagnosis to end of life and curative treatment to pallia-
tive treatment has been supported by research in psychosocial 
implications of coping with LC.30,31,39,41,43 Despite evidence of 
the benefits of psychosocial care, however, the financial support 
has lagged behind the support for treatment-related research, 
something that needs to improve in the next decade. The dis-
tress that affects significant others, particularly spouses, is prob-
ably underestimated.46 Some recent articles suggest that those 
significant others are affected by post-traumatic stress disorder 
of similar intensity than patients themselves; in this context, 
intrusive cognitions are the main factors.47 Hence, psychosocial 
care and meeting the needs of family caregivers are also areas 
that need further attention in the future.
PATIENT PERSONAL AND PSYCHOSOCIAL 
CHARACTERISTICS AND PROGNOSIS
There have been 30 years of research investigating 
patient characteristics and risks that would help to predict 
prognostic outcomes from treatment. The 1980s research arti-
cles were predominantly from physician researchers looking 
at risks and characteristics of patients who developed LC. The 
literature concentrated on examining risk factors that either 
improved or decreased prognosis in patients with LC includ-
ing cachexia and nutrition, performance status, pathology, 
age, psychosocial well-being, social isolation, smoking, and 
other exposures. Smoking and performance status were the 
two risk factors clearly shown to have an association with both 
developing LC and having poorer treatment outcomes.1,2
In 1989, Canadian researchers noted that adenocar-
cinoma did not have as strong an association with smoking, 
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it was often associated with women sex, and its frequency 
seemed to be increasing.48 Research continued to examine the 
themes of psychosocial well-being and social isolation finding 
positive correlations to better prognosis, with increased well-
being and decreased social isolation related to better performance 
status.1,30 In the past decade, there have been studies looking into 
the concept of social class contributing to LC mortality. One 
study examined a specific region in Scotland that had the high-
est incidence of LC in the world and found a positive correlation 
between lower social class and increased mortality.49 With the 
increased incidence in never smokers developing LC, the expo-
sures to second hand smoke and environmental pollutants have 
also been explored.49,50 Research attempting to identify additional 
risk factors has continued through to present time.50–53
QUALITY OF LIFE AND PATIENT-REPORTED 
OUTCOME MEASURES
The concept of quality of life has been prominent in 
oncology for several decades; but, the acronym of “PRO” for 
patient-reported outcomes is relatively new. As articulated in 
the US FDA 2006 draft document for guidance to industry 
related to outcome measures, a PRO can range from “...purely 
symptomatic (response of a headache) to more complex con-
cepts (e.g., ability to carry out activities of daily living), to 
extremely complex concepts such as quality of life, which is 
widely understood to be a multidomain concept with physical, 
psychological, and social components.” (p.1).54
Quality of life and PROs are now regarded as key assess-
ments in supportive care for patients and in clinical trials 
throughout a broad spectrum of human health. However, this 
was not always the case, as many considered PROs as “soft 
science” back in the 1980s compared with objective mea-
sures. Indeed, progress was slow but steady in refining PROs 
as useful endpoints for clinical trials. As previously presented 
by Gralla and Hollen55 in an overview of this progression for 
the concept of health-related quality of life, now under the 
umbrella of PROs, several historical markers became evident. 
Key developments in the PRO field54,56–59 are shown in Box 1.
One often overlooked turning point of development was 
an article in 1989 by Donovan et al.60 voicing a dilemma when 
reviewing 17 health-related quality of life instruments for cancer 
patients. The authors reported that only three of the 17 (18%) 
measures for specific use with cancer patients were judged to 
have adequate psychometric properties. In the past, other than a 
psychology course, health providers were often not exposed to 
psychometric properties. These properties refer to the evaluation 
of instruments to assure that they are feasible (defined as accept-
able to patients and staff for a chosen population and setting), 
reliable (consistent and reproducible), and valid (measure what 
they are supposed to measure). Other problems among PRO 
instruments included long questionnaires that lacked focus on 
clinically important areas, that risked collecting unnecessary or 
confounding information, or that resulted in missing data. Such 
problems can lead to increased patient burden, which is a par-
ticularly crucial consideration when measurement over time is 
expected for those with a declining illness trajectory.
To overcome these problems for quality of life mea-
sures, developers changed to concentrating assessment on 
dimensions or domains (often called “life areas”) of quality 
of life that were considered “health-related.” This resulted 
in a trend from developing generic health-related quality of 
life measures to those defined as disease-specific (e.g., can-
cer), site-specific (e.g., organ-specific, such as measures for 
LC), or treatment-specific (e.g., bone marrow transplant). 
This was accompanied in many cases by more thorough test-
ing to ensure that the instruments had acceptable psychomet-
ric properties for the population of interest. Currently, many 
disciplines are including an understanding of psychometric 
properties in masters or doctoral level study to help with 
choosing a PRO measure. There are now more than 800 mea-
sures presented on the Patient-Reported Outcome and Quality 
of Life Instruments Database website (www.proqolid.org) by 
Mapi Research Trust. Well-validated PRO instruments which 
reduce patient burden and which are based on established psy-
chometric principles are central to successful PRO evaluation. 
Three measures were reviewed favorably for LC by a commit-
tee from the National Cancer Institute61: EORTC QLQ-LC13, 
FACT-L, and LCSS.62–64 Each of these well-validated mea-
sures also have progressed from paper to electronic versions 
to overcome many of the barriers to their use.65–67
Several comprehensive reviews related to LC and qual-
ity of life exist in the literature. Montazeri et al.68 reviewed the 
related literature from 1970 to 1995 identifying 151 articles. 
Key messages from this review included that understanding 
quality of life issues is not only linked with improvements 
in the patients’ needs but also survival. As presented above, 
due to the slow progress of developing and testing well-vali-
dated and practical instruments, incorporating quality of life 
assessments in clinical practice was shown to be challenging. 
In more recent reviews, quality of life focuses on surgical 
patients with LC69 and the contribution of quality of life mea-
sures in the care of patients with LC70.
The rich development of PROs over a half century 
needs to be recognized and the progression not overlooked 
BOx 1. KEY DEVELOPMENTS IN PATIENT-REPORTED 
OUTCOMES
1949—Early development of the first performance sta-
tus measure of the Karnofsky Scale.56
1985—Food and Drug Administration ruling on new 
drugs that recognized quality of life as an end point 
in addition to survival.57
1996—American Society of Clinical Oncology treat-
ment guidelines reinforced that quality of life was 
one of three key endpoints for cancer clinical trials 
in addition to response and survival.58
2006—Guidelines for industry use of health and quality 
of life outcomes drafted by several regulatory bod-
ies, such as federal departments, including the US 
Department of Health and Human Services FDA 
Center for Drug Evaluation and Research.54
2012—Coming of age for monitoring health-related 
quality of life and patient-reported outcomes (PROs) 
in oncology clinical trials and daily practice.59
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or discredited by those new in the field. Future directions for 
PROs assessment include continued integration into research 
and practice to help with clinical decision-making and use of 
technology to enhance supportive care for LC.
THE OPTION OF BEST SUPPORTIVE CARE 
VERSUS TREATMENT
In the past decades, treatment for LC has evolved 
from cisplatin-based compounds to newer agents like peme-
trexed and the introduction of targeted and immune therapies. 
However, these new developments have only led to a modest 
increase in survival.71 Because of the noncurative possibili-
ties in advanced LC, treatment should be balanced for risks 
and benefits; survival needs to be weighed against toxicity 
and inconvenience.72 The “trade off ” between palliation and 
toxicity would be much more obvious during the later stages 
of the disease and for many patients simple nonchemothera-
peutic palliation will be the best available option because of 
the decline in quality of life.73,74 Brundage et al.75 studied sur-
vival benefits against the potential toxicity of different treat-
ment strategies for non–small-cell LC concluding that 80% of 
the patients were willing to consider a more toxic treatment 
when a survival advantage was offered. Sequentially, Silvestri 
et al.76 analyzed the cutoff between the survival benefit of che-
motherapy and its toxicities in advanced non–small-cell LC 
patients. In this descriptive study, only 22% of patients would 
consider chemotherapy with mild toxicity with a 3-month 
additional survival; 78% preferred best supportive care. 
However, a larger proportion of patients (68%) would choose 
chemotherapy if it substantially reduced symptoms without 
prolonging life.76 Hence, palliative treatment in LC needs to 
be balanced against toxicity, symptom reduction, and survival. 
PROs and health-related quality of life may provide us with 
essential information to use during shared decision-making.
TOBACCO CONTROL, SMOKING CESSATION, 
AND SUPPORTIVE CARE
The 40th anniversary for IASLC coincides with another 
important anniversary, the 50th anniversary of the first US 
Surgeon General’s report about the health consequences of 
smoking and the connection between smoking and prema-
ture death as well as disease in 196477. In the 1950s, studies 
revealed the increased risk of LC among smokers as compared 
with never smokers. Initially, the primary LC histology was 
squamous cell carcinoma, but the increase in adenocarcinoma 
since the 1960s is attributed to the changes in the design and 
composition of cigarettes.77 Smoking has declined from 42% 
in 1965 to 18% in 2012 in the US, but remains high in many 
parts of the world.78,79 In 1964, LC was rare among women, but 
since the mid 1980s, LC became the leading cause of cancer 
death among women in the US. The disparities in tobacco use 
among certain groups are associated with disparities in LC as 
well. In 1988, nicotine was recognized as the active agent in 
cigarettes that makes quitting so difficult. An evidence-based 
guideline for treating tobacco dependence first published in 
1996, updated in 2000 and 2008, highlighted the importance 
of addressing nicotine addiction as well as the need for psy-
chosocial support and skills training to increase quit efforts.80
New in the 2014 report, The Health Consequences of 
Smoking—50 Years of Progress, is evidence that continued 
smoking after a diagnosis of cancer leads to poorer health out-
comes.78 The Surgeon General Report concluded that the evi-
dence was sufficient to infer a causal relationship (1) between 
smoking and adverse health outcomes, (2) all-cause and can-
cer-specific mortality, and (3) that quitting smoking improves 
survival. The evidence is also sufficient to infer a causal 
relationship between smoking and increased risk for second 
primary cancers associated with cigarette smoking. Another 
important conclusion was that evidence was suggestive, but 
not sufficient, to infer a causal relationship between contin-
ued smoking and risk of recurrence, and poorer response to 
treatment.
A substantial minority of patients with LC do continue 
to smoke after diagnosis, and even those who quit are at risk 
for relapse.81,82 Support for tobacco cessation also can be 
viewed as an important part of the supportive care for patients 
who continue to smoke after a diagnosis of LC and their fam-
ily members.83 As described in the Surgeon General Report, 
interventions to help patients stop using tobacco are central 
to quality patient care.78 For survivors, tobacco cessation is 
especially important as smoking is associated with a long list 
of diseases including chronic obstructive pulmonary disease 
and heart disease as well as second cancers that can also com-
promise quantity and quality of life. Among the new diseases 
added in the latest Surgeon General Report as caused by ciga-
rette smoking are liver cancer, colorectal cancer, diabetes, and 
stroke.78 Even for patients with advanced LC, smoking should 
be addressed as it can be a safety issue for the patient and oth-
ers. The evidence for the health risks associated with exposure 
to second hand smoke also continue to be important as it is 
causally associated with increased risk of LC78.
Assessing tobacco use and providing tobacco-depen-
dent treatment has not been routinely included as part of either 
cancer research or supportive care for patients with cancer in 
designated cancer centers in the US84,85 and elsewhere in the 
world. However, the interventions described in Tobacco Use 
and Dependence Clinical Practice Guideline: 2008 Guideline 
are effective for all smokers.80 Key components of effec-
tive tobacco-dependent treatment include social support and 
pharmacotherapy. Strategies described as the “5 As” (i.e., 
ask about tobacco use, advise patients to quit using tobacco, 
assess patient’s readiness to quit, assist with tobacco cessation, 
and arrange for follow-up) provide a schema for intervention 
and are recommended for every patient at every encounter. 
Another effective resource in many countries for supporting 
patients’ quit efforts are telephone quitlines (e.g., 1 800 QUIT 
NOW in the United States). Trained counselors provide edu-
cation and support during a quit attempt. Interventions can 
be effectively delivered by nurses86 and involvement of oncol-
ogy nurses in the delivery of a tobacco-dependent treatment 
intervention is in keeping with the Oncology Nursing Society 
policy on tobacco control and the policies of the American 
Society for Clinical Oncology.87,88
Unfortunately, oncology healthcare providers have not 
provided adequate support to patients with cancer in their quit 
efforts.89 This is a concern as treatment is needed to address 
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withdrawal and suffering from nicotine during a smoke-free 
hospital stay, similar to the management of other symptoms 
such as pain. However, healthcare professionals can make a 
difference if adequately prepared. To address this need, the 
American Society for Clinical Oncology has a range of mate-
rials aimed at supporting quit efforts of patients with cancer 
that can be used by oncology healthcare professionals.90 Based 
on the guideline,80 these materials provide nonjudgmental evi-
dence-based supportive interventions.
There are a number of barriers that need to be addressed 
in order for oncology healthcare providers to consistently 
implement comprehensive and effective smoking cessation 
interventions as part of supportive care for patients with LC. 
These include limited knowledge and skills, lack of system 
support, and continued smoking among healthcare profession-
als, including nurses. There are a growing number of resources 
to help educate healthcare providers about this area91 and the 
expectations for quality healthcare include addressing tobacco 
use.92 Smoking among healthcare providers varies widely.93 
Not only is a risk factor for health and well-being but also it 
interferes with interventions with patients. Policy changes are 
needed to ensure that treatment of tobacco dependence occurs 
during the entire continuum of LC care.94 Addressing tobacco 
use as part of supportive care is an important part of reducing 
cancer-related morbidity and mortality.95
SERVICE PROVISION AND MODELS OF 
SUPPORTIVE CARE IN PATIENTS WITH LC
In 2001, patients with LC were shown to experience 
greater burden of distress than other cancer groups.96 This 
review of evidence published over the past 40 years of ser-
vice enhancements with regards to optimizing supportive care 
needs for people affected by LC indicates that the community 
has been slow to respond to the magnitude of unmet needs 
among this group. It was not until 1989 that findings from 
a randomized controlled trial of a home care intervention 
demonstrated the potential of novel service delivery models 
(nurse-led and home based in this instance) to patient out-
comes, including symptom distress, enforced social depen-
dency, and health perceptions which were all significantly 
better in the two home care groups as compared with office-
care group.97 In a recent Cochrane systematic review of non-
invasive interventions for improving well-being and quality 
of life in patients with LC,98 only four trials of care delivery 
programs were identified and one of these was the article from 
1989. An article published on the effect of detailed symptom 
assessment on patient symptom experience99 lents support to 
McCorkle’s97 findings that structured nursing assessment can 
lead to improvements in symptom distress over time. A ran-
domized controlled trial of 203 patients with LC comparing 
nurse-led to conventional medical follow-up100 reported that 
patients in the nurse-led follow-up arm were more likely to 
die at home, attend fewer medical consultations and have 
more radiotherapy within the first 3 months of diagnosis than 
patients in traditional medical follow-up. In a study of 140 
patients with LC receiving palliative radiotherapy, patients 
were randomized to an educational package plus coaching of 
progressive muscle relaxation or to control group, who received 
usual care; the authors demonstrated that the nursing program 
led to improvements in breathlessness, fatigue, anxiety, and 
functional ability.101 But perhaps one of the most influential 
recent articles reporting on models of care enhancements for 
people with LC has come from Temel et al.,23 as mentioned 
earlier. They randomized 151 patients with newly diagnosed 
metastatic non–small-cell LC (n = 107 evaluable patients) to 
receive either palliative care early after diagnosis integrated 
with standard care or standard care alone. Patients assigned to 
early palliative care had significantly better quality of life than 
did patients assigned to standard care; had significantly fewer 
depressive symptoms; and despite patients in the early pallia-
tive care group receiving less aggressive end-of-life care than 
patients in the standard care arm, median survival was longer 
among patients receiving early palliative care.
Supporting the early integration of palliative care for 
patients with advanced cancer, Zimmermann et al.102 in a 
Canadian, cluster-randomized controlled trial of 24 medical 
oncology clinics (461 patients) demonstrated that patients in 
clinics randomized to consultation and follow-up by a pallia-
tive care team demonstrated significantly better PROs (qual-
ity of life, symptom burden and experience and satisfaction 
with care of outpatients with advanced cancer) than patients 
attending clinics providing standard cancer care at 4-month 
postrandomization.
Further to the Cochrane reviews, Schofield et al.16 
reported equivocal outcomes for patients with LC randomized 
to a model of nurse-led follow-up postcompletion of initial 
treatment to standard care. The intervention patients had access 
to a specialist nurse and contact through an open access clinic, 
message pager service, and telephone assessment. In another 
trial, patients with LC and their caregivers randomized to a 14 
telephone-based sessions of either caregiver-assisted coping 
skills training or education/support involving the caregiver or 
education/caregiver support, reported improved pain, depres-
sion, quality of life and self-efficacy (patients) or improved 
anxiety and quality of life (caregivers) for the coping skills 
training arm.103 In addition to data illustrating the benefit of 
nursing to a comprehensive model of LC care, recent evidence 
from a large, LC educational intervention program, funded by 
the National Cancer Institute in the USA, has demonstrated 
potential benefits of integrating social work to the care of 
patients as a component of early palliative care intervention.104
This brief review of service provision and models of sup-
portive care in LC demonstrates that more robust research is 
needed to develop and test novel approaches to care delivery 
for people affected by LC. In 2014, there is a wealth of data 
from descriptive studies that offer important insight into key 
components of novel, patient-centered, supportive care ser-
vice models in LC. These include a single point of contact to 
provide timely advice with regard to changing symptom pro-
files or severity that can help prevent unnecessary emergency 
department presentations105,106; interventions that address anxi-
ety, vulnerability, and uncertainty,107 particularly when patients 
are away from regular hospital contact108; service models that 
offer home-based and remote monitoring100; early integration 
of palliative care,109 timely provision of information to general 
practitioners110 and importantly, models of service delivery that 
16 Copyright © 2014 by the International Association for the Study of Lung Cancer
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attend to the needs of informal caregivers to enable them to 
continue caring for and optimizing supportive care outcome 
of patients as well as contributing to better caregiver psycho-
logical outcomes into bereavement.111 Nurse-led and shared 
care models of service delivery are acceptable to patients with 
LC105. Studies rigorously testing web-based or ehealth technol-
ogies to ensure equity of access to evidence-based services for 
patients with LC, irrespective of where they live, are urgently 
needed.
CONCLUSION
The rapidly expanding and multi-disciplinary field 
of supportive care in LC has played a major role in under-
standing the patients’ needs and illness challenges, provided 
evidence from interventional work and highlighted the sig-
nificant role of supportive care, not only in meeting the needs 
of the patients but also in improving survival. As treatment 
protocols are improving and new treatments are introduced, 
managing toxicity will be of paramount importance in the 
future. Symptom-control research will continue to domi-
nate the field but there is an urgent need to develop more 
effective interventions and focus on an array of neglected 
symptoms alongside the common ones. Moreover, there is 
a vital need to not only test effective but also cost–effective 
ways of managing symptoms and toxicity with more meth-
odologically robust studies. Identification of the physical, 
psychosocial, and existential needs for patients with LC will 
continue to be a priority, but with a strong focus on support-
ive end-of-life care. A newer concept, survivorship in LC, is 
in its infancy, but as patients live longer (albeit still a small 
percentage of them) models of care to meet the patient’s 
needs, including smoking cessation, become crucial foci for 
research and practice.
Despite the many developments in supportive care over 
the past 40 years and major contributions, supportive care 
in LC is less visible compared with supportive care in other 
cancer diagnoses. How this will change, both in the eyes of 
patients and clinicians alike, will be worth discussing in the 
near future. IASLC, as the leading organization in the study 
of LC, has a key role to play in providing the appropriate and 
necessary strategic leadership in this area.
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